{"product_id":"fulgentgenetics-business-model-canvas","title":"Fulgent Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Business Model Canvas: strategic playbook for investors, founders, and advisors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Fulgent’s strategic playbook with the full Business Model Canvas—detailing value propositions, customer segments, key partners, revenue streams, and cost drivers. Ideal for investors, consultants, and founders, this editable Word\/Excel file turns research into actionable strategy; download now to benchmark, plan, and scale with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and health system alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with hospitals and health systems secure steady sample inflows and enable integrated care pathways by embedding Fulgent workflows into clinical order and reporting systems. Embedded lab workflows reduce friction for ordering and accelerate result delivery to electronic health records. Co-development of testing protocols ensures alignment with clinical standards, while joint outcome studies support reimbursement and inclusion in clinical guidelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and research institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with academic and research institutions supply assay innovation and validation cohorts, giving Fulgent access to rare disease populations across roughly 7,000 known rare conditions, ~80% of which are genetic. Peer‑reviewed publications from these collaborations boost clinical adoption, while grant‑backed studies (NIH FY2024 appropriation ~50 billion) lower R\u0026amp;D risk and cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSequencing and technology vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRelationships with leading NGS platform providers (Illumina holds roughly 70% of the short‑read market) secure cutting‑edge instruments and volume pricing for Fulgent. Co‑optimization of assays and workflows measurably improves accuracy, throughput and TAT across high‑volume pipelines. Joint roadmaps with vendors ensure scalability and reliability while preferred support agreements minimize instrument downtime.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and biotech for companion diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-development with pharma and biotech links Fulgent's tests to targeted therapies, enabling joint submission pathways and co-marketing with drug launches.\u003c\/p\u003e\n\u003cp\u003eBiomarker discovery and validation partnerships expand Fulgent's test menus and support regulatory-grade evidence generation for new indications.\u003c\/p\u003e\n\u003cp\u003eCompanion diagnostic approvals open new clinical markets and payer pathways, while sponsored testing programs accelerate oncologist adoption and real-world uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development: therapy alignment\u003c\/li\u003e\n\u003cli\u003eBiomarkers: menu expansion\u003c\/li\u003e\n\u003cli\u003eCDx approvals: market access\u003c\/li\u003e\n\u003cli\u003eSponsored testing: faster clinician adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and healthcare networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContracts with payers and networks secure coverage and predictable reimbursement, expanding patient access for Fulgent's genomic tests.\u003c\/p\u003e\n\u003cp\u003eData sharing aligns medical policies by integrating real-world evidence into payer guidelines, while value dossiers quantify clinical and economic benefits for coverage decisions.\u003c\/p\u003e\n\u003cp\u003eStreamlined prior authorization workflows reduce approval time and accelerate ordering and test utilization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage \u0026amp; reimbursement\u003c\/li\u003e\n\u003cli\u003eMedical policy alignment\u003c\/li\u003e\n\u003cli\u003eValue dossiers: clinical + economic\u003c\/li\u003e\n\u003cli\u003eFaster prior authorization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital EHR integrations secure samples; academic assays cover \u003cstrong\u003e7,000\u003c\/strong\u003e rare diseases (\u003cstrong\u003e80%\u003c\/strong\u003e genetic)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital integrations embed Fulgent workflows into EHRs to secure steady sample inflows; academic partnerships supply assay validation across ~7,000 rare diseases, ~80% genetic; vendor ties with Illumina (roughly 70% short‑read market) secure instruments and volume pricing; payer contracts and value dossiers drive coverage and faster prior authorization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/research\u003c\/td\u003e\n\u003ctd\u003eRare disease coverage\u003c\/td\u003e\n\u003ctd\u003e~7,000 conditions; ~80% genetic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS vendors\u003c\/td\u003e\n\u003ctd\u003eMarket share (short‑read)\u003c\/td\u003e\n\u003ctd\u003eIllumina ~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal R\u0026amp;D funding\u003c\/td\u003e\n\u003ctd\u003eNIH appropriation FY2024\u003c\/td\u003e\n\u003ctd\u003e~$50 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas tailored to Fulgent’s strategy, organized into the 9 classic BMC blocks with full narrative, insights, and competitive advantage analysis. Ideal for presentations, funding discussions, and decision-making, it links SWOT findings to each block and supports validation using real company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for Fulgent that condenses strategy into a one-page snapshot, saving hours on formatting and enabling teams to quickly identify core components and adapt the model for boards, comparisons, or fast deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssay development and validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning targeted panels for rare disease, oncology, reproductive and infectious use cases, Fulgent prioritizes breadth and clinical relevance while leveraging sequencing costs near USD 600–1,000 per genome (2024) to optimize economics. Analytical and clinical validation follows CLIA, CAP and FDA-aligned standards with performance targets typically exceeding 99% sensitivity for SNVs and high reproducibility. Continuous iteration adds new genes and biomarkers quarterly to capture emerging evidence. Detailed validation dossiers and health‑economic documentation support payer coverage and guideline inclusion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-throughput sequencing operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-throughput sequencing operations at Fulgent cover sample accessioning, automated extraction, library prep, and multiplexed NGS runs to support clinical panels and large-scale screens. Automation drives scale and consistency, enabling throughput reported in 2024 alongside corporate revenue of $486.5 million. Rigorous QC protocols aim to keep reruns minimal and TAT optimized to meet clinical turnaround targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and interpretation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Fulgent operates proprietary pipelines for variant calling, annotation, and classification that feed a curated clinical knowledgebase to improve actionability. The team continuously curates evidence and reclassifies variants to reduce uncertain findings and increase diagnostic yield. Clinician-facing reports translate complex results into clear, actionable insights. A rules engine and models are regularly updated to reflect new guidelines and literature.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and data security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent maintains CLIA\/CAP accreditation with mandatory ongoing proficiency testing, strict SOP governance and continuous audit readiness; labs use documented change control and quarterly internal audits. Data protection aligns with HIPAA and GDPR standards through encryption, access controls and incident response; risk management includes formalized post-market surveillance and CAPA workflows to address quality or safety signals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCLIA\/CAP: ongoing proficiency testing, audit readiness\u003c\/li\u003e\n\u003cli\u003eSOP governance: version control, internal audits\u003c\/li\u003e\n\u003cli\u003eData security: HIPAA\/GDPR-aligned encryption \u0026amp; IR\u003c\/li\u003e\n\u003cli\u003eRisk \u0026amp; post-market: surveillance, CAPA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial enablement and provider education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOnboarding clinicians and health systems via streamlined workflows and EMR-integrated ordering increases test adoption; medical affairs drive KOL engagement to validate clinical utility and influence guidelines. Dedicated coding, billing and reimbursement support reduces denials and accelerates payment cycles. Robust digital tools and developer-facing APIs enable seamless ordering, reporting and EHR integration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnboarding: clinician and system integration\u003c\/li\u003e\n\u003cli\u003eMedical affairs: KOL development\u003c\/li\u003e\n\u003cli\u003eBilling: coding \u0026amp; reimbursement support\u003c\/li\u003e\n\u003cli\u003eDigital: APIs \u0026amp; EHR integrations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically focused NGS panels — \u003cstrong\u003e\u0026gt;99%\u003c\/strong\u003e SNV sensitivity, optimized TAT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent designs clinically focused NGS panels (rare disease, oncology, infectious) leveraging genome costs ~USD 600–1,000 (2024) to balance breadth and margins; validations follow CLIA\/CAP\/FDA-aligned standards with \u0026gt;99% SNV sensitivity and quarterly panel updates. High-throughput automated labs support 2024 revenue USD 486.5M and optimized TAT; pipelines, QC, and payer support drive adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eUSD 486.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenome cost\u003c\/td\u003e\n\u003ctd\u003eUSD 600–1,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSNV sensitivity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Fulgent Business Model Canvas you’re previewing is the exact document you’ll receive after purchase; it’s not a mockup or sample. When you buy, you’ll get this same fully formatted, ready-to-edit file in Word and Excel formats. No surprises—what you see is the final deliverable, complete and downloadable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162268938617,"sku":"fulgentgenetics-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/fulgentgenetics-business-model-canvas.png?v=1762698157","url":"https:\/\/portersfiveforce.com\/products\/fulgentgenetics-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}